85-3969-85　Pranlukast 50mg　CAS No:103177-37-3　286999

特徴

• Cysteinyl leukotriene receptor antagonist. The cysteinyl leukotrienes (CysLTs) LTC4 and LTD4 are potent mediators of asthma and hypersensitivity. They induce bronchoconstriction, increase microvascular permeability, and are vasoconstrictors of coronary arteries. Their biological effects are transduced by a pair of G protein-coupled receptors, CysLT1 and CysLT2.1,2,3 Pranlukast (ONO-1078) is a potent, selective and orally active cysteinyl leukotriene1 (CysLT1) receptor antagonist.4 Sold under the trade name Ultair, it was the first cysteinyl (peptidyl) leukotriene receptor antagonist (LTRA) marketed for the treatment of asthma.5 Clinical studies in Japan, Europe, and North America all show that pranlukast significantly attenuates bronchoconstriction in response to a variety of allergen challenges as well as to inhaled LTD4.5 Pranlukast binds to the human CysLT1 and CysLT2 receptors with IC50 values of approximately 4-7nM and 3,600nM, respectively.
• Synonyms:N-{4-Oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide; ONO-1078; ONO-RS-411; Onon; Ultair
• Molecular Formula:C₂₇H₂₃N₅O₄
• Molecular Weight:481.50
• Purity:≥98%
• Appearance:White to off-white crystalline powder
• Melting Point:236-238°C (lit)
• Solubility:Soluble in DMSO at 10mg/ml and DMF at 20mg/ml.
• Storage and Stability:May be stored at -20°C. Stable for 6 months after receipt at -20°C. Reconstitute with sterile buffer. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
• Important Note:This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
• Toxicity and Hazards: All products should be handled by qualified personnel only, trained in laboratory procedures.